Emulation of Randomized Clinical Trial in Cardiovascular Disease (RCT-BigData)
Effects of PPI on GI Bleeding and Cardiovascular Outcomes Among Post-MI Patients Taking DAPT
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Ki Hong Choi, MD
- Phone Number: 82-2-3410-3419
- Email: cardiokh@gmail.com
Study Contact Backup
- Name: Danbee Kang, PhD
- Phone Number: 82-2-2148-7197
- Email: dbee.kang@skku.edu
Study Locations
-
-
-
Seoul, Korea, Republic of
- Recruiting
- Samsung Medical Center
-
Contact:
- Ki Hong Choi, MD
- Phone Number: 82-2-3410-3419
- Email: cardiokh@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- - PCI with MI (I21) admission
- Age more than 40 or less than 80 years old
- Aspirin and Clopidogrel/Prasugrel/Ticagrelor prescription with more than 2 days at discharge
Exclusion Criteria:
- - Previous use of a PPI, an H2-receptor antagonist, sucralfate, or misoprostol within 30 days before admission
- Preexisting cancer within a year before admission
- History of RBC transfusion
- RBC transfusion in admission
- Cardiogenic Shock
- Length of stay more than 14 days
- OAC prescription with more than 2 days at discharge
- H2 prescription with more than 2 days at discharge
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PPI group
Patients receiving PPI concomitant with dual antiplatelet therapy after PCI for AMI
|
use of PPI concomitant with DAPT
Other Names:
|
|
no PPI group
Patients receiving dual antiplatelet therapy only after PCI for AMI
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rates of Major GI bleeding requiring transfusion
Time Frame: 1-year follow-up
|
Efficacy outcome
|
1-year follow-up
|
|
Rates of Major adverse cardiac event
Time Frame: 1-year follow-up
|
Safety outcome, a composite of cardiac death, MI, ischemic stroke, and repeat revascularization
|
1-year follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rates of Major or Minor GI bleeding with hospitalization
Time Frame: 1-year follow-up
|
Efficacy outcome
|
1-year follow-up
|
|
Rates of Cardiac death
Time Frame: 1-year follow-up
|
Cardiac death
|
1-year follow-up
|
|
Rates of Spontaneous MI
Time Frame: 1-year follow-up
|
Spontaneous MI
|
1-year follow-up
|
|
Rates of Ischemic stroke
Time Frame: 1-year follow-up
|
Ischemic stroke
|
1-year follow-up
|
|
Rates of Repeat revascularization
Time Frame: 1-year follow-up
|
Repeat revascularization
|
1-year follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ki Hong Choi, MD, Samsung Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CVD-Emulation
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.